Apogee Therapeutics
APGE
73 hedge funds and large institutions have $849M invested in Apogee Therapeutics in 2023 Q3 according to their latest regulatory filings, with 73 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
107.85% more ownership
Funds ownership: 0% → 107.85% (+108%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$187M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$97.8M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$64.8M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$53.2M |
| 5 |
RI
RTW Investments
New York
|
+$47.2M |
Top Sellers
APGE Hedge Fund Activity: Q3 2023 in Review
73 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q3 2023, worth a combined $849M.
Buyers outnumbered sellers: 73 funds opened new APGE positions and 0 closed out — a net gain of 73 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $187M.
- 73 institutional investors held Apogee Therapeutics (APGE) as of Q3 2023, up from 0 in Q2 2023.
- Funds reported $849M of Apogee Therapeutics stock for Q3 2023.
- 73 funds opened new Apogee Therapeutics positions in Q3 2023 and 0 closed out, a net change of +73 holders.
- The largest Apogee Therapeutics buyer in Q3 2023 was VR Adviser, an estimated $187M added.
Based on aggregated 13F filings for Q3 2023.